Correlation Between Prime Medicine, and Cns Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Prime Medicine, and Cns Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Prime Medicine, and Cns Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Prime Medicine, Common and Cns Pharmaceuticals, you can compare the effects of market volatilities on Prime Medicine, and Cns Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Prime Medicine, with a short position of Cns Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Prime Medicine, and Cns Pharmaceuticals.

Diversification Opportunities for Prime Medicine, and Cns Pharmaceuticals

0.52

Correlation Coefficient

Prime Medicine,  Cns Pharmaceuticals

Very weak diversification

The 3 months correlation between Prime and Cns is 0.52. Overlapping area represents the amount of risk that can be diversified away by holding Prime Medicine, Common and Cns Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cns Pharmaceuticals and Prime Medicine, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Prime Medicine, Common are associated (or correlated) with Cns Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cns Pharmaceuticals has no effect on the direction of Prime Medicine, i.e., Prime Medicine, and Cns Pharmaceuticals go up and down completely randomly.

Pair Corralation between Prime Medicine, and Cns Pharmaceuticals

Given the investment horizon of 90 days Prime Medicine, Common is expected to under-perform the Cns Pharmaceuticals. But the etf apears to be less risky and, when comparing its historical volatility, Prime Medicine, Common is 1.35 times less risky than Cns Pharmaceuticals. The etf trades about -0.05 of its potential returns per unit of risk. The Cns Pharmaceuticals is currently generating about -0.02 of returns per unit of risk over similar time horizon. If you would invest  14.00  in Cns Pharmaceuticals on September 26, 2024 and sell it today you would lose (3.00) from holding Cns Pharmaceuticals or give up 21.43% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Prime Medicine, Common  vs.  Cns Pharmaceuticals

Prime Medicine, Common

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Prime Medicine, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Etf's primary indicators remain rather sound which may send shares a bit higher in January 2025. The latest tumult may also be a sign of longer-term up-swing for the fund shareholders.

Cns Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Cns Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with latest weak performance, the Stock's basic indicators remain invariable and the latest agitation on Wall Street may also be a sign of long-running gains for the enterprise retail investors.

Pair Trading with Prime Medicine, and Cns Pharmaceuticals

The main advantage of trading using opposite Prime Medicine, and Cns Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Prime Medicine, position performs unexpectedly, Cns Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cns Pharmaceuticals will offset losses from the drop in Cns Pharmaceuticals' long position.

The idea behind Prime Medicine, Common and Cns Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.